vs
Esperion Therapeutics, Inc.（ESPR）与IBEX Ltd（IBEX）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是IBEX Ltd的1.0倍（$168.4M vs $164.2M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 16.7%），过去两年IBEX Ltd的营收复合增速更高（13.8% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
IBEX 35是西班牙主要交易所马德里证券交易所的基准股票指数，该指数始创于1992年，由西班牙证券市场集团BME旗下的交易所公司负责计算与管理。它以市值加权编制，涵盖马德里证券交易所流动性最高的35只西班牙股票，每年进行两次成分股调整。
ESPR vs IBEX — 直观对比
营收规模更大
ESPR
是对方的1.0倍
$164.2M
营收增速更快
ESPR
高出127.0%
16.7%
两年增速更快
IBEX
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $164.2M |
| 净利润 | — | $12.2M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 9.3% |
| 净利率 | — | 7.4% |
| 营收同比 | 143.7% | 16.7% |
| 净利润同比 | — | 31.8% |
| 每股收益（稀释后） | $0.32 | $0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRIBEX
| Q4 25 | $168.4M | $164.2M | ||
| Q3 25 | $87.3M | $151.2M | ||
| Q2 25 | $82.4M | $147.1M | ||
| Q1 25 | $65.0M | $140.7M | ||
| Q4 24 | $69.1M | $140.7M | ||
| Q3 24 | $51.6M | $129.7M | ||
| Q2 24 | $73.8M | $124.5M | ||
| Q1 24 | $137.7M | $126.8M |
净利润ESPRIBEX
| Q4 25 | — | $12.2M | ||
| Q3 25 | $-31.3M | $12.0M | ||
| Q2 25 | $-12.7M | $9.6M | ||
| Q1 25 | $-40.5M | $10.5M | ||
| Q4 24 | — | $9.3M | ||
| Q3 24 | $-29.5M | $7.5M | ||
| Q2 24 | $-61.9M | $9.8M | ||
| Q1 24 | $61.0M | $10.3M |
营业利润率ESPRIBEX
| Q4 25 | 50.6% | 9.3% | ||
| Q3 25 | -11.4% | 9.1% | ||
| Q2 25 | 8.6% | 8.3% | ||
| Q1 25 | -34.0% | 9.5% | ||
| Q4 24 | -6.4% | 8.5% | ||
| Q3 24 | -31.0% | 7.0% | ||
| Q2 24 | 3.5% | 10.3% | ||
| Q1 24 | 52.5% | 8.9% |
净利率ESPRIBEX
| Q4 25 | — | 7.4% | ||
| Q3 25 | -35.9% | 8.0% | ||
| Q2 25 | -15.4% | 6.5% | ||
| Q1 25 | -62.2% | 7.4% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | -57.2% | 5.8% | ||
| Q2 24 | -83.9% | 7.9% | ||
| Q1 24 | 44.3% | 8.1% |
每股收益（稀释后）ESPRIBEX
| Q4 25 | $0.32 | $0.83 | ||
| Q3 25 | $-0.16 | $0.82 | ||
| Q2 25 | $-0.06 | $0.63 | ||
| Q1 25 | $-0.21 | $0.73 | ||
| Q4 24 | $-0.14 | $0.57 | ||
| Q3 24 | $-0.15 | $0.43 | ||
| Q2 24 | $-0.33 | $0.55 | ||
| Q1 24 | $0.34 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $15.5M |
| 总债务越低越好 | — | $594.0K |
| 股东权益账面价值 | $-302.0M | $154.5M |
| 总资产 | $465.9M | $295.8M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资ESPRIBEX
| Q4 25 | $167.9M | $15.5M | ||
| Q3 25 | $92.4M | $22.7M | ||
| Q2 25 | $86.1M | $15.3M | ||
| Q1 25 | $114.6M | $13.0M | ||
| Q4 24 | $144.8M | $20.2M | ||
| Q3 24 | $144.7M | $62.3M | ||
| Q2 24 | $189.3M | $62.7M | ||
| Q1 24 | $226.6M | $50.7M |
总债务ESPRIBEX
| Q4 25 | — | $594.0K | ||
| Q3 25 | — | $726.0K | ||
| Q2 25 | — | $796.0K | ||
| Q1 25 | — | $735.0K | ||
| Q4 24 | — | $695.0K | ||
| Q3 24 | — | $802.0K | ||
| Q2 24 | — | $867.0K | ||
| Q1 24 | — | $820.0K |
股东权益ESPRIBEX
| Q4 25 | $-302.0M | $154.5M | ||
| Q3 25 | $-451.4M | $143.6M | ||
| Q2 25 | $-433.5M | $134.3M | ||
| Q1 25 | $-426.2M | $124.2M | ||
| Q4 24 | $-388.7M | $108.9M | ||
| Q3 24 | $-370.2M | $171.1M | ||
| Q2 24 | $-344.2M | $165.8M | ||
| Q1 24 | $-294.3M | $159.3M |
总资产ESPRIBEX
| Q4 25 | $465.9M | $295.8M | ||
| Q3 25 | $364.0M | $283.9M | ||
| Q2 25 | $347.1M | $273.2M | ||
| Q1 25 | $324.0M | $274.7M | ||
| Q4 24 | $343.8M | $272.5M | ||
| Q3 24 | $314.1M | $306.3M | ||
| Q2 24 | $352.3M | $293.9M | ||
| Q1 24 | $373.1M | $289.6M |
负债/权益比ESPRIBEX
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | — | 0.01× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $6.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.1M |
| 自由现金流率自由现金流/营收 | — | -3.1% |
| 资本支出强度资本支出/营收 | 0.0% | 7.1% |
| 现金转化率经营现金流/净利润 | — | 0.54× |
| 过去12个月自由现金流最近4个季度 | — | $29.3M |
8季度趋势，按日历期对齐
经营现金流ESPRIBEX
| Q4 25 | $45.2M | $6.6M | ||
| Q3 25 | $-4.3M | $15.7M | ||
| Q2 25 | $-31.4M | $27.9M | ||
| Q1 25 | $-22.6M | $8.8M | ||
| Q4 24 | $-35.0M | $1.1M | ||
| Q3 24 | $-35.3M | $7.8M | ||
| Q2 24 | $-7.2M | $17.4M | ||
| Q1 24 | $53.8M | $11.4M |
自由现金流ESPRIBEX
| Q4 25 | — | $-5.1M | ||
| Q3 25 | — | $8.0M | ||
| Q2 25 | — | $22.8M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $-3.2M | ||
| Q3 24 | $-35.5M | $4.1M | ||
| Q2 24 | $-7.3M | $15.2M | ||
| Q1 24 | $53.8M | $9.7M |
自由现金流率ESPRIBEX
| Q4 25 | — | -3.1% | ||
| Q3 25 | — | 5.3% | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -68.7% | 3.2% | ||
| Q2 24 | -9.9% | 12.2% | ||
| Q1 24 | 39.0% | 7.7% |
资本支出强度ESPRIBEX
| Q4 25 | 0.0% | 7.1% | ||
| Q3 25 | 0.0% | 5.1% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 3.7% | ||
| Q4 24 | 0.0% | 3.1% | ||
| Q3 24 | 0.3% | 2.8% | ||
| Q2 24 | 0.1% | 1.8% | ||
| Q1 24 | 0.1% | 1.3% |
现金转化率ESPRIBEX
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 2.91× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 0.12× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.77× | ||
| Q1 24 | 0.88× | 1.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
IBEX
| Transferred Over Time | $147.1M | 90% |
| Transferred At Point In Time | $17.1M | 10% |
